The use of the finasteride-adjusted prostate cancer prevention trial prostate cancer risk calculator in a mexican referral population: A validation study

Yuanyuan Liang, Norma S. Ketchum, Christopher Louden, Miguel A. Jimenez-Rios, Ian M. Thompson, Hector R. Camarena-Reynoso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: To perform the first validation study of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (finPCPTRC) in a contemporary referral population in Mexico. Methods: 837 patients referred to the Instituto Nacional de Cancerologa, Mexico City, Mexico, between 2005 and 2009 were used to validate the finPCPTRC by examining various measures of discrimination and calibration. Net benefit curve analysis was used to gain insight into the use of the finPCPTRC for clinical decisions. Results: Prostate cancer (PCa) incidence (72.8%) was high in this Mexican referral cohort and 45.7% of men who were diagnosed with PCa had high-grade lesions (HGPCa, Gleason score >6). 1.3% of the patients were taking finasteride. The finPCPTRC was a superior diagnostic tool compared to prostate-specific antigen alone when discriminating patients with PCa from those without PCa (AUC = 0.784 vs. AUC = 0.687, p < 0.001) and when discriminating patients with HGPCa from those without HGPCa (AUC = 0.768 vs. AUC = 0.739, p < 0.001). The finPCPTRC underestimated the risk of PCa but overestimated the risk of HGPCa (both p < 0.001). Compared with other strategies to opt for biopsy, the net benefit would be larger with utilization of the finPCPTRC for patients accepting higher risks of HGPCa. Conclusions: Rates of biopsy-detectable PCa and HGPCa were high and 1.3% of this referral cohort in Mexico was taking finasteride. The risks of PCa or HGPCa calculated by the finPCPTRC were not well calibrated for this referral Mexican population and new clinical diagnostic tools are needed.

Original languageEnglish (US)
Pages (from-to)9-16
Number of pages8
JournalUrologia Internationalis
Volume89
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Finasteride
Validation Studies
Prostatic Neoplasms
Referral and Consultation
Population
Mexico
Area Under Curve

Keywords

  • Finasteride
  • Mexico
  • Prostate cancer
  • Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator
  • Prostate-specific antigen

ASJC Scopus subject areas

  • Urology

Cite this

The use of the finasteride-adjusted prostate cancer prevention trial prostate cancer risk calculator in a mexican referral population : A validation study. / Liang, Yuanyuan; Ketchum, Norma S.; Louden, Christopher; Jimenez-Rios, Miguel A.; Thompson, Ian M.; Camarena-Reynoso, Hector R.

In: Urologia Internationalis, Vol. 89, No. 1, 07.2012, p. 9-16.

Research output: Contribution to journalArticle

Liang, Yuanyuan ; Ketchum, Norma S. ; Louden, Christopher ; Jimenez-Rios, Miguel A. ; Thompson, Ian M. ; Camarena-Reynoso, Hector R. / The use of the finasteride-adjusted prostate cancer prevention trial prostate cancer risk calculator in a mexican referral population : A validation study. In: Urologia Internationalis. 2012 ; Vol. 89, No. 1. pp. 9-16.
@article{9e471941e7b0461aa163fceab8f5f09e,
title = "The use of the finasteride-adjusted prostate cancer prevention trial prostate cancer risk calculator in a mexican referral population: A validation study",
abstract = "Objectives: To perform the first validation study of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (finPCPTRC) in a contemporary referral population in Mexico. Methods: 837 patients referred to the Instituto Nacional de Cancerologa, Mexico City, Mexico, between 2005 and 2009 were used to validate the finPCPTRC by examining various measures of discrimination and calibration. Net benefit curve analysis was used to gain insight into the use of the finPCPTRC for clinical decisions. Results: Prostate cancer (PCa) incidence (72.8{\%}) was high in this Mexican referral cohort and 45.7{\%} of men who were diagnosed with PCa had high-grade lesions (HGPCa, Gleason score >6). 1.3{\%} of the patients were taking finasteride. The finPCPTRC was a superior diagnostic tool compared to prostate-specific antigen alone when discriminating patients with PCa from those without PCa (AUC = 0.784 vs. AUC = 0.687, p < 0.001) and when discriminating patients with HGPCa from those without HGPCa (AUC = 0.768 vs. AUC = 0.739, p < 0.001). The finPCPTRC underestimated the risk of PCa but overestimated the risk of HGPCa (both p < 0.001). Compared with other strategies to opt for biopsy, the net benefit would be larger with utilization of the finPCPTRC for patients accepting higher risks of HGPCa. Conclusions: Rates of biopsy-detectable PCa and HGPCa were high and 1.3{\%} of this referral cohort in Mexico was taking finasteride. The risks of PCa or HGPCa calculated by the finPCPTRC were not well calibrated for this referral Mexican population and new clinical diagnostic tools are needed.",
keywords = "Finasteride, Mexico, Prostate cancer, Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator, Prostate-specific antigen",
author = "Yuanyuan Liang and Ketchum, {Norma S.} and Christopher Louden and Jimenez-Rios, {Miguel A.} and Thompson, {Ian M.} and Camarena-Reynoso, {Hector R.}",
year = "2012",
month = "7",
doi = "10.1159/000338270",
language = "English (US)",
volume = "89",
pages = "9--16",
journal = "Urologia Internationalis",
issn = "0042-1138",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - The use of the finasteride-adjusted prostate cancer prevention trial prostate cancer risk calculator in a mexican referral population

T2 - A validation study

AU - Liang, Yuanyuan

AU - Ketchum, Norma S.

AU - Louden, Christopher

AU - Jimenez-Rios, Miguel A.

AU - Thompson, Ian M.

AU - Camarena-Reynoso, Hector R.

PY - 2012/7

Y1 - 2012/7

N2 - Objectives: To perform the first validation study of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (finPCPTRC) in a contemporary referral population in Mexico. Methods: 837 patients referred to the Instituto Nacional de Cancerologa, Mexico City, Mexico, between 2005 and 2009 were used to validate the finPCPTRC by examining various measures of discrimination and calibration. Net benefit curve analysis was used to gain insight into the use of the finPCPTRC for clinical decisions. Results: Prostate cancer (PCa) incidence (72.8%) was high in this Mexican referral cohort and 45.7% of men who were diagnosed with PCa had high-grade lesions (HGPCa, Gleason score >6). 1.3% of the patients were taking finasteride. The finPCPTRC was a superior diagnostic tool compared to prostate-specific antigen alone when discriminating patients with PCa from those without PCa (AUC = 0.784 vs. AUC = 0.687, p < 0.001) and when discriminating patients with HGPCa from those without HGPCa (AUC = 0.768 vs. AUC = 0.739, p < 0.001). The finPCPTRC underestimated the risk of PCa but overestimated the risk of HGPCa (both p < 0.001). Compared with other strategies to opt for biopsy, the net benefit would be larger with utilization of the finPCPTRC for patients accepting higher risks of HGPCa. Conclusions: Rates of biopsy-detectable PCa and HGPCa were high and 1.3% of this referral cohort in Mexico was taking finasteride. The risks of PCa or HGPCa calculated by the finPCPTRC were not well calibrated for this referral Mexican population and new clinical diagnostic tools are needed.

AB - Objectives: To perform the first validation study of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator (finPCPTRC) in a contemporary referral population in Mexico. Methods: 837 patients referred to the Instituto Nacional de Cancerologa, Mexico City, Mexico, between 2005 and 2009 were used to validate the finPCPTRC by examining various measures of discrimination and calibration. Net benefit curve analysis was used to gain insight into the use of the finPCPTRC for clinical decisions. Results: Prostate cancer (PCa) incidence (72.8%) was high in this Mexican referral cohort and 45.7% of men who were diagnosed with PCa had high-grade lesions (HGPCa, Gleason score >6). 1.3% of the patients were taking finasteride. The finPCPTRC was a superior diagnostic tool compared to prostate-specific antigen alone when discriminating patients with PCa from those without PCa (AUC = 0.784 vs. AUC = 0.687, p < 0.001) and when discriminating patients with HGPCa from those without HGPCa (AUC = 0.768 vs. AUC = 0.739, p < 0.001). The finPCPTRC underestimated the risk of PCa but overestimated the risk of HGPCa (both p < 0.001). Compared with other strategies to opt for biopsy, the net benefit would be larger with utilization of the finPCPTRC for patients accepting higher risks of HGPCa. Conclusions: Rates of biopsy-detectable PCa and HGPCa were high and 1.3% of this referral cohort in Mexico was taking finasteride. The risks of PCa or HGPCa calculated by the finPCPTRC were not well calibrated for this referral Mexican population and new clinical diagnostic tools are needed.

KW - Finasteride

KW - Mexico

KW - Prostate cancer

KW - Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator

KW - Prostate-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84864595067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864595067&partnerID=8YFLogxK

U2 - 10.1159/000338270

DO - 10.1159/000338270

M3 - Article

C2 - 22626812

AN - SCOPUS:84864595067

VL - 89

SP - 9

EP - 16

JO - Urologia Internationalis

JF - Urologia Internationalis

SN - 0042-1138

IS - 1

ER -